4.93 USD
▼-0.28-5.37%
盘后 4.80 -2.64%
2026-09-15
市值
$441.77M
市盈率
—
EPS
-1.09
股息率
—
52 周区间
1.88 – 7.44
成交量
2.64M
Beta
-0.03
目标价
18.00
52W 低 1.8852W 高 7.44
价格走势
公司简介
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and C...